021-51111890
购物车（）
sales@molnova.cn
β-Casomorphin (1-5), bovine
CAS No. 72122-63-5
β-Casomorphin (1-5), bovine ( —— )
产品货号. M29964 CAS No. 72122-63-5
β-Casomorphin Fragment 1-5 (BCM5), an opioid receptor agonist, is a member of the β-casomorphin peptide family derived from β-casein. β-casomorphins are used to study their differential effects on processes such as hyperglycemia, oxidative stress, opioid signalling and immunosuppression.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
生物学信息
-
产品名称β-Casomorphin (1-5), bovine
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述β-Casomorphin Fragment 1-5 (BCM5), an opioid receptor agonist, is a member of the β-casomorphin peptide family derived from β-casein. β-casomorphins are used to study their differential effects on processes such as hyperglycemia, oxidative stress, opioid signalling and immunosuppression.
-
产品描述β-Casomorphin Fragment 1-5 (BCM5), an opioid receptor agonist, is a member of the β-casomorphin peptide family derived from β-casein. β-casomorphins are used to study their differential effects on processes such as hyperglycemia, oxidative stress, opioid signalling and immunosuppression.
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体——
-
研究领域——
-
适应症——
化学信息
-
CAS Number72122-63-5
-
分子量579.6
-
分子式C30H37N5O7
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
Sagittatoside A
Sagittatoside A selectively activates estrogen response element (ERE)-luciferase activity via ERα.
-
Methyl nomilinate
Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.
-
Quercetin 7-O-(6-O-m...
Quercetin 7-O-(6''-O-malonyl)-beta-D-glucoside is a natural product of Justicia, Acanthaceae. Quercetin 7-O-(6''-O-malonyl)-beta-D-glucoside can be used as a reference standard.
